Matthew Fowler, Associate Editor

home / authors / matthew-fowler-associate-editor

Articles

HER2+ Breast Cancer Clinical Pearls

HER2+ Breast Cancer Clinical Pearls

Virginia Kaklamani, MD, DSc;Matthew Fowler, Associate Editor
February 15th 2022

Advice for community physicians treating HER2+ breast cancer.

HER2+ Breast Cancer and the Role of Maintenance Therapies

HER2+ Breast Cancer and the Role of Maintenance Therapies

Virginia Kaklamani, MD, DSc;Matthew Fowler, Associate Editor
February 8th 2022

Dr. Virginia Kaklamani discusses the role of maintenance therapies for HER2+ breast cancer.

Clinical Trial Data in HER2+ Breast Cancer

Clinical Trial Data in HER2+ Breast Cancer

Virginia Kaklamani, MD, DSc;Matthew Fowler, Associate Editor
February 8th 2022

Virginia Kaklamani, MD, DSc, provides an overview of the goals of care for HER2+ breast cancer.

HER2+ Breast Cancer: Frontline Treatment Options

HER2+ Breast Cancer: Frontline Treatment Options

Virginia Kaklamani, MD, DSc;Matthew Fowler, Associate Editor
February 1st 2022

A review of the currently available frontline treatment options for HER2+ breast cancer.

Goals of Care for HER2+ Breast Cancer

Goals of Care for HER2+ Breast Cancer

Virginia Kaklamani, MD, DSc;Matthew Fowler, Associate Editor
February 1st 2022

Virginia Kaklamani, MD, DSc, provides an overview of the goals of care for HER2+ breast cancer.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
Published: May 11th 2022 | Updated: April 21st 2025
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma